SPONSOR
Astellas Pharma Korea, Inc.
Total Trials
2
Recruiting
2
Phases
N/A
Conditions studied: Urothelial CancerLocally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or CancerMetastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
NCT06011954
Recruiting
A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection
Urothelial Cancer
NCT06902545
Recruiting
A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer